Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials

Akbari, Elahe; Seyedinkhorasani, Masoud; Bolhassani, Azam

doi:10.1016/j.bjid.2023.102774

Cited by 6 publications

(2 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HIV-1 lipopeptide vaccine serves as an example of such a vaccine and is presently undergoing clinical trials. 29 Utilizing multi-epitope proteins for diagnosis or vaccine development offers the advantage of preventing cross-reactivity. Epitopes can be selected using bioinformatic tools such as BLAST or ClustalW, which compare genomes and proteomes to identify regions with polymorphisms.…”

Section: Discussionmentioning

confidence: 99%

Development and assessment of a multiepitope synthetic antigen for the diagnosis of Dengue virus infection

da Silva,

de Moraes Rodrigues,

Batista

et al. 2024

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Development and assessment of a multiepitope synthetic antigen for the diagnosis of Dengue virus infection

da Silva,

de Moraes Rodrigues,

Batista

et al. 2024

The Brazilian Journal of Infectious Diseases

View full text Add to dashboard Cite

“…Multi-epitope subunit vaccines represent an effective means to induce cross-reactive cell-mediated immune responses and have shown effectiveness in infectious disease and cancer control ( 31 , 32 ). They are produced via recombinant DNA technology and offer robust immunogenicity, safety, and scalability.…”

Section: Introductionmentioning

confidence: 99%

Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine

Kolla,

Dutt,

Kumar

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

IntroductionBluetongue (BT) poses a significant threat to the livestock industry, affecting various animal species and resulting in substantial economic losses. The existence of numerous BT virus (BTV) serotypes has hindered control efforts, highlighting the need for broad-spectrum vaccines.MethodologyIn this study, we evaluated the conserved amino acid sequences within key non-structural (NS) proteins of BTV and identified numerous highly conserved murine- and bovine-specific MHC class I-restricted (MHC-I) CD8+ and MHC-II-restricted CD4+ epitopes. We then screened these conserved epitopes for antigenicity, allergenicity, toxicity, and solubility. Using these epitopes, we developed in silico-based broad-spectrum multiepitope vaccines with Toll-like receptor (TLR-4) agonists. The predicted proinflammatory cytokine response was assessed in silico using the C-IMMSIM server. Structural modeling and refinement were achieved using Robetta and GalaxyWEB servers. Finally, we assessed the stability of the docking complexes through extensive 100-nanosecond molecular dynamics simulations before considering the vaccines for codon optimization and in silico cloning.ResultsWe found many epitopes that meet these criteria within NS1 and NS2 proteins and developed in silico broad-spectrum vaccines. The immune simulation studies revealed that these vaccines induce high levels of IFN-γ and IL-2 in the vaccinated groups. Protein-protein docking analysis demonstrated promising epitopes with strong binding affinities to TLR-4. The docked complexes were stable, with minimal Root Mean Square Deviation and Root Mean Square Fluctuation values. Finally, the in silico-cloned plasmids have high % of GC content with > 0.8 codon adaptation index, suggesting they are suitable for expressing the protein vaccines in prokaryotic system.DiscussionThese next-generation vaccine designs are promising and warrant further investigation in wet lab experiments to assess their immunogenicity, safety, and efficacy for practical application in livestock. Our findings offer a robust framework for developing a comprehensive, broad-spectrum vaccine, potentially revolutionizing BT control and prevention strategies in the livestock industry.

show abstract

Dual‐acting HIV Inhibitors

Camarasa,

San‐Félix,

de Castro

2024

Polypharmacology

View full text Add to dashboard Cite

Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials

Cited by 6 publications

References 95 publications

Development and assessment of a multiepitope synthetic antigen for the diagnosis of Dengue virus infection

Development and assessment of a multiepitope synthetic antigen for the diagnosis of Dengue virus infection

Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine

Dual‐acting HIV Inhibitors

Contact Info

Product

Resources

About